Press Release Archive
-
Johnson & Johnson to Participate in Cowen 40th Annual Health Care ConferenceJohnson & Johnson to Participate in Cowen 40th Annual Health Care Conference
-
Johnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 TreatmentsJohnson & Johnson to Expand Partnership with U.S. Department of Health & Human Services to Accelerate the Discovery of Potential COVID-19 TreatmentsJanssen strengthens collaboration with Biomedical Advanced Research and Development Authority (BARDA) in an effort to stem the threat of the global COVID-19 outbreak
-
Johnson & Johnson to Participate in the 9th Annual SVB Leerink Global Healthcare ConferenceJohnson & Johnson to Participate in the 9th Annual SVB Leerink Global Healthcare Conference
-
Johnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus VaccineJohnson & Johnson Announces Collaboration with U.S. Department of Health & Human Services to Accelerate Development of a Potential Novel Coronavirus VaccineJanssen joins forces with Biomedical Advanced Research and Development Authority (BARDA) to protect communities against threat of a global COVID-19 pandemic
-
Janssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple MyelomaJanssen Announces Submission to U.S. FDA for New DARZALEX® (Daratumumab)-Based Combination Regimen for Patients with Relapsed/Refractory Multiple Myeloma· Application is based on positive data from the Phase 3 CANDOR study, which were presented at the 2019 American Society of Hematology Annual Meeting
-
Janssen to Highlight Depth of Solid Tumor Portfolio at ASCO GUJanssen to Highlight Depth of Solid Tumor Portfolio at ASCO GUNew data featured in multiple presentations across prostate and bladder cancer treatment portfolio and pipeline including ERLEADA® (apalutamide), niraparib and BALVERSATM (erdafitinib)
-
Johnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health ThreatJohnson & Johnson Launches Multi-Pronged Response to Coronavirus Global Public Health ThreatInitiating Vaccine Development and Providing Supplies of Antiviral Medicines to China for Investigational Use
-
Johnson & Johnson Announces $250 Million Commitment to Support Frontline Health Workers, Reaching 100 Million People By 2030Johnson & Johnson Announces $250 Million Commitment to Support Frontline Health Workers, Reaching 100 Million People By 2030Center for Health Worker Innovation will catalyze efforts to respond to human resource crisis in global health and build a thriving health workforce
-
Johnson & Johnson Reports 2019 Fourth-Quarter and Full Year ResultsJohnson & Johnson Reports 2019 Fourth-Quarter and Full Year Results· 2019 Fourth-Quarter Sales of $20.7 Billion reflecting growth of 1.7%, operational growth of 2.6%* and adjusted operational growth of 3.4%*
· 2019 Full-Year Sales of $82.1 Billion reflecting growth of 0.6%, operational growth of 2.8%* and adjusted operational growth of 4.5%*
· 2019 Fourth-Quarter EPS of $1.50 increased 33.9%; adjusted EPS of $1.88 decreased 4.6%*
· 2019 Full-Year EPS of $5.63 increased 0.4%; adjusted EPS of $8.68 increased 6.1%*
· Company projects continued sales and earnings growth in 2020 guidance -
Johnson & Johnson Collaborates with The MTV Staying Alive Foundation to Launch Youth-Focused “Edutainment” Campaign Focused on Tuberculosis & Other Health Issues in IndiaJohnson & Johnson Collaborates with The MTV Staying Alive Foundation to Launch Youth-Focused “Edutainment” Campaign Focused on Tuberculosis & Other Health Issues in IndiaProgram aims to raise awareness and reduce stigma of TB among young people in India, as part of Johnson & Johnson’s 10-year initiative to combat world’s leading infectious disease killer